## Sevtap Arikan-Akdagli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2302204/publications.pdf

Version: 2024-02-01

623734 395702 1,551 31 14 33 citations h-index g-index papers 36 36 36 2123 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
2	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
3	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
4	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients ( <scp>FUNDICU</scp> ) project. Mycoses, 2019, 62, 310-319.	4.0	53
5	Head-to-Head Comparison of Inhibitory and Fungicidal Activities of Fluconazole, Itraconazole, Voriconazole, Posaconazole, and Isavuconazole against Clinical Isolates of Trichosporon asahii. Antimicrobial Agents and Chemotherapy, 2013, 57, 4841-4847.	3.2	46
6	Distribution, virulence attributes and antifungal susceptibility patterns of <i>Candida parapsilosis </i> complex strains isolated from clinical samples. Medical Mycology, 2013, 51, 483-492.	0.7	30
7	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	3.5	29
8	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. Clinical Infectious Diseases, 2021, 72, 1379-1385.	5 <b>.</b> 8	28
9	Epidemiology of candidaemia in a tertiary care university hospital: 10â€year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses, 2015, 58, 498-505.	4.0	24
10	Evaluation of Antifungal Efficacy of 0.1% and 0.25% Riboflavin with UVA: A Comparative In Vitro Study. Current Eye Research, 2016, 41, 1050-1056.	1.5	23
11	Species distribution, azole resistance and related molecular mechanisms in invasive <i>Candida parapsilosis</i> complex isolates: Increase in fluconazole resistance in 21 years. Mycoses, 2021, 64, 823-830.	4.0	22
12	First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. Journal of Global Antimicrobial Resistance, 2019, 18, 230-234.	2.2	20
13	ECMM <i>Candi</i> Regâ€"A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
14	Azole resistance in <i>Aspergillus</i> : global status in Europe and Asia. Annals of the New York Academy of Sciences, 2012, 1272, 9-14.	3.8	18
15	Fungal infections of the skin and soft tissue. Current Opinion in Infectious Diseases, 2020, 33, 130-136.	3.1	14
16	MixInYeast: A Multicenter Study on Mixed Yeast Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 13.	3.5	14
17	Candidaemia in a paediatric centre and importance of central venous catheter removal. Mycoses, 2015, 58, 140-148.	4.0	13
18	In vitro activities of antifungal drugs against environmental $\langle i \rangle$ Exophiala $\langle i \rangle$ isolates and review of the literature. Mycoses, 2018, 61, 561-569.	4.0	12

#	Article	IF	CITATIONS
19	Fungaemia due to rare yeasts in a tertiary care university centre within 18 years. Mycoses, 2020, 63, 488-493.	4.0	10
20	Frequency of azole resistance in clinical and environmental strains of <i>Aspergillus fumigatus</i> in Turkey: a multicentre study. Journal of Antimicrobial Chemotherapy, 2022, 77, 1894-1898.	3.0	9
21	Investigation of Intestinal Protozoon Prevalence in Immunocompromised Patients at a University Hospital. Turkiye Parazitolojii Dergisi, 2021, 45, 39-44.	0.6	8
22	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. Mycoses, 2020, 63, 420-429.	4.0	7
23	A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints. Journal of Fungi (Basel, Switzerland), 2022, 8, 141.	3 <b>.</b> 5	6
24	Influence of serum on <i>in vitro</i> susceptibility testing of echinocandins for <i>Candida parapsilosis</i> and <i>Candida guilliermondii</i> Mycoses, 2012, 55, 156-160.	4.0	4
25	Aspergillus terreus Infection in a Sutureless Self-sealing Incision Made During Cataract Surgery. Mycopathologia, 2015, 179, 129-134.	3.1	4
26	Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1539-1545.	2.9	3
27	Is COVID-19 a risk factor for invasive pulmonary aspergillosis in critically ill patients?. Tuberkuloz Ve Toraks, 2021, 69, 118-120.	0.4	2
28	A Rare Presentation of Pulmonary Aspergillosis. Journal of Bronchology and Interventional Pulmonology, 2020, 27, e28-e33.	1.4	1
29	Clinical implications of fungal isolation from sputum in adult patients with cystic fibrosis. Turkish Journal of Medical Sciences, 2021, 51, 1191-1200.	0.9	1
30	The Emergence of Echinocandin-Resistant Candida glabrata Exhibiting High MICs and Related FKS Mutations in Turkey. Journal of Fungi (Basel, Switzerland), 2021, 7, 691.	<b>3.</b> 5	1
31	Fungal Drug Resistance Assays. , 2017, , 1367-1387.		1